Ignite Creation Date:
2025-12-24 @ 6:59 PM
Ignite Modification Date:
2026-02-20 @ 7:22 PM
Study NCT ID:
NCT07272057
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-09
First Post:
2025-11-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes
Sponsor:
Shanghai Chest Hospital
Organization:
Study Overview
Official Title:
The Impact of SGLT2i on the Outcome of Advanced Lung Cancer in Patients With Diabetes
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial
The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and diabetes. It will also check if these drugs are safe for these patients. The main questions it aims to answer are:
* Does adding an SGLT2 inhibitor to standard cancer treatment improve survival?
* Does it cause more or fewer cardiovascular toxicity?
* What side effects do participants experience? Researchers will compare a group taking an SGLT2 inhibitor to a group not taking SGLT2 inhibitor to see if the drug works.
Participants will:
* Be adults diagnosed with advanced lung cancer and type 2 diabetes.
* Take either the SGLT2 inhibitor pill or other hypoglycemic drugs once a day alongside their cancer treatment.
* Undergo regular clinical visits for monitoring, laboratory tests, and imaging studies
The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and diabetes. It will also check if these drugs are safe for these patients. The main questions it aims to answer are:
* Does adding an SGLT2 inhibitor to standard cancer treatment improve survival?
* Does it cause more or fewer cardiovascular toxicity?
* What side effects do participants experience? Researchers will compare a group taking an SGLT2 inhibitor to a group not taking SGLT2 inhibitor to see if the drug works.
Participants will:
* Be adults diagnosed with advanced lung cancer and type 2 diabetes.
* Take either the SGLT2 inhibitor pill or other hypoglycemic drugs once a day alongside their cancer treatment.
* Undergo regular clinical visits for monitoring, laboratory tests, and imaging studies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: